Brad Constant, MD

Assistant Professor, Pediatrics-Gastroenterology, Hepatology and Nutrition

Faculty Photo
Medical School
  • MD, Florida Atlantic University, Charles E. Schmidt College of Medicine (2015)
Graduate School
  • MSCS, University of Colorado Denver (2021)
Undergraduate School
  • BS, Stonehill College (MA) (2011)
Internship
  • Children's National Medical Center/George Washington University Program (2016)
Residency
  • Children's National Medical Center/George Washington University Program, Pediatrics (2018)
Fellowships
  • University of Colorado (Children's Hospital Colorado) Program, Pediatric Gastroenterology (2021)
  • Children's Hospital of Philadelphia Program, Advanced Inflammatory Bowel Disease (2023)
Languages
English
Department
Pediatrics-Gastroenterology, Hepatology and Nutrition

Professional Titles

  • Assistant Professor

Research Interests

My research interests are centered around improving the care of children with inflammatory bowel disease. These include 1) causal inference-based research methods to inform common yet challenging clinical scenarios faced by pediatric gastroenterologists, and 2) outline the burden and impact of insurance-related barriers to care faced by patients with inflammatory bowel disease, develop strategies to counteract these processes, and participate in advocacy efforts aimed at reform.

Publications

  • Larson C, Berinstein JA, Tedesco N, Seidelin JB, Ovesen PD, Uzzan M, Amiot A, Nuzzo A, Laharie D, Constant BD, Albenberg L, El-Hussuna A, Bishu S, Cohen-Mekelburg S, Higgins PDR, Steenholdt C. Postoperative Outcomes in Tofacitinib-Treated Patients With Acute Severe Ulcerative Colitis Undergoing Colectomy. Clin Gastroenterol Hepatol. 2025 Nov;23(12):2263-2271.e6. PubMed PMID: 40239733
  • Constant BD, Adler J, Gold BD, Dotson J, Lightdale JR, Scott F, Saeed S, Kim S, Moses J, de Zoeten EF, Mirea L, Ritchey A, Pasternak B. National perspectives of barriers by insurance and pharmacy benefit managers in pediatric inflammatory bowel disease. JPGN Rep. 2025 May;6(2):80-90. PubMed PMID: 40386337
  • Constant BD, Long MD, Scott FI, Higgins PDR. Insurer-Mandated Medication Utilization Barriers are Associated With Decreased Insurance Satisfaction and Adverse Clinical Outcomes: An Inflammatory Bowel Disease Partners Survey. Am J Gastroenterol. 2024 Oct 1;119(10):2070-2078. PubMed PMID: 38819004
  • Beukelman T, Chen L, Annapureddy N, Oates J, Clowse MEB, Long M, Kappelman MD, Rhee RL, Merkel PA, Nowell WB, Xie F, Clinton C, Curtis JR. Using pooled electronic health records data to conduct pharmacoepidemiology safety studies: Challenges and lessons learned. Pharmacoepidemiol Drug Saf. 2023 Sep;32(9):969-977. PubMed PMID: 37005701
  • Constant BD, de Zoeten EF, Weinman JP, Albenberg L, Scott FI. Early Anti-Tumor-Necrosis-Factor Therapy for Crohn's Disease-Related Abdominal Abscesses and Phlegmon in Children. Dig Dis Sci. 2023 Mar;68(3):877-888. PubMed PMID: 35790702
  • Dawwas GK, Weiss A, Constant BD, Parlett LE, Haynes K, Yang JY, Brensinger C, Wu Q, Pate V, Jonsson Funk M, Schaubel DE, Hurtado-Lorenzo A, David Kappelman M, Lewis JD. Development and Validation of Claims-Based Definitions to Identify Incident and Prevalent Inflammatory Bowel Disease in Administrative Healthcare Databases. Inflamm Bowel Dis. 2023 Apr 12. [Epub ahead of print] PubMed PMID: 37043675
  • Constant BD, Scott FI. The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance?. Dig Dis Sci. 2023 Dec;68(12):4279-4281. PubMed PMID: 37792128
  • Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, Dawwas GK, Weiss A, Constant BD, McCauley M, Haynes K, Yang JY, Schaubel DE, Hurtado-Lorenzo A, Kappelman MD. Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States. Gastroenterology. 2023 Nov;165(5):1197-1205.e2. PubMed PMID: 37481117
  • Constant BD, Albenberg L, Mitchel EB, De Zoeten EF, Clapp JT, Scott FI. Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey. Clin Gastroenterol Hepatol. 2023 Jun 30. [Epub ahead of print] PubMed PMID: 37394025
  • Dawwas GK, Weiss A, Constant BD, Parlett LE, Haynes K, Yang JY, Brensinger C, Wu Q, Pate V, Jonsson Funk M, Schaubel DE, Hurtado-Lorenzo A, David Kappelman M, Lewis JD. Development and Validation of Claims-Based Definitions to Identify Incident and Prevalent Inflammatory Bowel Disease in Administrative Healthcare Databases. Inflamm Bowel Dis. 2023 Dec 5;29(12):1993-1996. PubMed PMID: 37043675
  • Constant BD, Albenberg L, Mitchel EB, de Zoeten EF, Clapp JT, Scott FI. Prior Authorizations Delay Therapy, Impact Decision Making, and Lead to Adverse Events in IBD: 2022 Provider Survey. Clin Gastroenterol Hepatol. 2023 Jun 30. [Epub ahead of print] PubMed PMID: 37394025
  • Constant BD, de Zoeten EF, Weinman JP, Albenberg L, Scott FI. Early Anti-Tumor-Necrosis-Factor Therapy for Crohn's Disease-Related Abdominal Abscesses and Phlegmon in Children. Dig Dis Sci. 2023 Mar;68(3):877-888. PubMed PMID: 35790702
  • Constant BD, de Zoeten EF, Stahl MG, Vajravelu RK, Lewis JD, Fennimore B, Gerich ME, Scott FI. Delays Related to Prior Authorization in Inflammatory Bowel Disease. Pediatrics. 2022 Mar 1;149(3). PubMed PMID: 35190811
  • Constant BD, Dutmer CM, Arnold MA, Hall C, Abbott JK, de Zoeten EF. Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult-to-Treat Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 Apr;20(4):e696-e702. PubMed PMID: 33965572
  • Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2022 Dec 1;75(6):724-730. PubMed PMID: 36122389
  • Constant BD, de Zoeten EF, Stahl MG, Vajravelu RK, Lewis JD, Fennimore B, Gerich ME, Scott FI. Delays Related to Prior Authorization in Inflammatory Bowel Disease. Pediatrics. 2022 Mar 1;149(3). PubMed PMID: 35190811
  • Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2022 Dec 1;75(6):724-730. PubMed PMID: 36122389
  • Constant BD, Dutmer CM, Arnold MA, Hall C, Abbott JK, de Zoeten EF. Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult-to-Treat Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 Apr;20(4):e696-e702. PubMed PMID: 33965572
  • Constant BD, Khushal S, Jiang J, Bost JE, Chaisson E, Conklin LS. Early Inflammatory Markers are Associated With Inadequate Post-Induction Infliximab Trough in Pediatric Crohn's Disease. J Pediatr Gastroenterol Nutr. 2021 Mar 1;72(3):410-416. PubMed PMID: 33439565
  • Constant BD, Weinman JP, Stahl MG. Dissecting Duodenal Hematoma: A Rare but Serious Complication of Esophagogastroduodenoscopy. JPGN Rep. 2021 May;2(2):e052. PubMed PMID: 37207074
View All (20 Total) View Less

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Hospital Affiliation
  • Children's Hospital Colorado

Center Affiliations

Specialty Information

Specialties
  • Pediatrics, Board Certification (2018)
  • Pediatric Gastroenterology, Board Certification (2021, 2021)
Conditions & Treatments
  • Digestive System - Inflammatory Bowel Disease (IBD): Crohn’s disease, ulcerative colitis, microscopic colitis
  • Digestive System
  • Digestive System - Gastroenterology (Stomach, Bowel, General GI Problems)

School of Medicine

CU Anschutz

Fitzsimons Building

13001 East 17th Place

Campus Box C290

Aurora, CO 80045


303.724.5375